Diabetes is becoming more common as poor lifestyle choices continue to be prominent around the world. Insulin pens are a widely used method of treating diabetic individuals. Given this, Future Market Insights predicts that insulin pen sales will reach US$ 30,407 million in 2021.
Insulin pens are used by diabetes patients to avoid problems including cardiovascular diseases that may arise from this lifestyle-based ailment. To overcome problems related to conventional methods of insulin administration, insulin pens make the process easier and faster.
Get More Information on this Report @ https://www.futuremarketinsights.com/reports/insulin-pens-market
According to the WHO, approximately 1.2 million deaths were caused due to diabetes in 2019 globally. To reduce the number of deaths or sufferings due to diabetes, the development of innovative techniques and products for the treatment and maintenance of diabetes is essential.
Type 2 diabetes cases are common, but it can be prevented or delayed by a healthy diet, consistent physical activity, maintaining a standard body weight and avoiding the use of tobacco. Diabetes can be treated or managed with medicines and regular checking and treatment. Increasing focus on innovative medical products and research are increasingly driving a transition towards insulin pen by diabetes patients.
Leading manufacturers in the insulin pen market are strengthening their market position through collaborations with various health and research organizations. Governments in developed and developing countries are actively taking initiatives to encourage innovative medical products.
Key Takeaways from Insulin Pen Services Market Study
• Reusable insulin pens are expected to account for over 49% the global market share by 2031, supported by a growing base of environment and cost-conscious consumers.
• Hospital pharmacies will account for 33.8% of the market share in 2031. The soaring influx of patients for treatment and intensive care support supports growth.
• The U.S. is projected to be the fastest-growing regional market with a CAGR of 5.6% through 2021-2031 owing to the matured healthcare sector of the country.
• The U.K. and Germany are leading markets in Europe, accounting for more than 18% and 25% in 2021.
• China is the largest and fastest growing market in East Asia, exhibiting a 4.7% CAGR through 2031.
• Australia is leading the Oceania market, accounting for more than 85% of insulin pen revenues in 2021.
Insulin Pen Market - Key Companies Profiled
• NovoNordisk A/S
• Sanofi
• Eli Lilly
• Diamesco Co., Ltd.
• BigFoot Biomedical, Inc
• Medtronic plc
• Emperra GmbH E-Health Technologies
• YpsoMed AG
• DUKADA Aps